BOSTON, MA – March 11, 2026 – Intrinsic Therapeutics, Inc., a medical technology company redefining the standard of care for lumbar discectomy patients with large annular defects, today announced that Michael Briseño, MD, of North Texas Orthopedic & Spine Center and Texas Health Orthopedic & Spine Surgery Center Heritage, has achieved designation as a Barricaid® Platinum Center of Excellence.
This distinction recognizes consistent clinical excellence and a long-term commitment to improving outcomes for high-risk discectomy patients through the thoughtful use of Barricaid®.
“Dr. Briseño’s Platinum Center of Excellence designation reflects an ongoing commitment to surgical excellence and patient-centered care,” said Jake Tanner, VP of Marketing at Intrinsic Therapeutics. “His work demonstrates the impact of thoughtful patient selection, surgical precision, and a focus on durable outcomes for patients at elevated risk of reherniation.”
The Barricaid® is a bone-anchored annular closure device designed to close large annular defects following limited lumbar discectomy. By addressing the defect during surgery, Barricaid has been shown to reduce the risk of reoperation for reherniation by 81%1 in indicated patients. The Barricaid Center of Excellence program recognizes high-performing physicians and care teams that are advancing spine care through the consistent and effective use of the technology.
“I’m honored to receive this Platinum Center of Excellence designation,” said Dr. Michael Briseño. “This recognition reflects the commitment of our teams at North Texas Orthopedic & Spine Center and Texas Health Orthopedic & Spine Surgery Center Heritage to delivering thoughtful, evidence-based care. We remain focused on improving patient outcomes through surgical precision, strong clinical judgment, and the use of technologies that support long-term success.”
About Barricaid®
Barricaid is a proprietary technology designed to prevent reherniation and reduce the risk of reoperation in patients with large annular defects following lumbar discectomy surgery. Barricaid has been implanted in more than 13,000 patients and is supported by clinical studies across eight distinct patient populations, including two randomized controlled trials and six single-arm studies. A multicenter, Level I RCT demonstrating superior outcomes compared to discectomy alone was published in JAMA with five-year follow-up results.
*Some studies are outside FDA indications. Values at a minimum of 1-year post-op. Minimum study size: 20 Barricaid subjects.
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.